✦ LIBER ✦
24 Zoledronic acid (ZOL) as add-on therapy in patients with tumour residuals after neoadjuvant chemotherapy for primary breast cancer – first interim safety analysis of the NATAN study (GBG 36)
✍ Scribed by G. von Minckwitz; M.D. Zahm; H. Eidtmann; H. Tesch; A. du Bois; K. Schwedler; J. Hilfrich; C. Jackisch; K. Mehta; B. Gerber
- Book ID
- 119601041
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 47 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.